文献速递乳腺癌支持与姑息治疗

肌钙蛋白I和T及N末端脑钠肽前体在监测接受曲妥珠单抗治疗的早期人表皮生长因子受体2阳性乳腺癌患者心脏安全性中的作用:赫赛汀辅助研究心脏标志物亚研究

Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.
PubMed 文献 · J Clin Oncol · 2016-10-23

该研究基于赫赛汀辅助(HERA)研究,纳入533例同意参与本研究的早期HER2阳性乳腺癌患者,其中452例可评估。基线肌钙蛋白I升高(>40 ng/L)和肌钙蛋白T升高(>14 ng/L)分别见于56/412例(13.6%)和101/407例(24.8%),均与显著左心室射血分数(LVEF)下降风险增加相关(单变量分析:风险比4.52,P<.001;风险比3.57,P<.001)。NT-proBNP因缺乏公认的升高阈值而无法得出类似结论,但发生心脏终点事件的患者其较基线的升高幅度更大。

要点

  • 曲妥珠单抗治疗前肌钙蛋白I>40 ng/L或T>14 ng/L与显著LVEF下降风险增加相关。
  • NT-proBNP缺乏公认的升高阈值,无法得出其预测曲妥珠单抗相关心脏功能障碍的结论。
  • 发生心脏终点事件的患者NT-proBNP较基线升高幅度更大。

核心结论

  • 曲妥珠单抗治疗前肌钙蛋白I或T升高与曲妥珠单抗相关心脏功能障碍风险增加相关。
  • NT-proBNP因缺乏公认的升高阈值而无法得出类似结论,但发生心脏终点事件的患者其较基线升高幅度更大。

研究设计与样本

  • 本研究为赫赛汀辅助(HERA)研究的心脏标志物亚研究,纳入533例同意参与本研究的早期HER2阳性乳腺癌患者,最终452例可评估。
  • 在不同时间点将心脏标志物检测与LVEF测量配对进行。
  • 主要心脏终点定义为经心脏科医生确认的纽约心脏协会III或IV级症状性充血性心力衰竭和显著LVEF下降,或明确或可能因心脏原因导致的死亡。
  • 次要心脏终点定义为确认的显著无症状或轻度症状性LVEF下降。

主要发现

  • 基线肌钙蛋白I升高(>40 ng/L)见于56/412例(13.6%),基线肌钙蛋白T升高(>14 ng/L)见于101/407例(24.8%)。
  • 基线肌钙蛋白I升高与显著LVEF下降风险增加相关(单变量分析:风险比4.52,P<.001)。
  • 基线肌钙蛋白T升高与显著LVEF下降风险增加相关(单变量分析:风险比3.57,P<.001)。
  • 研究期间首次记录到肌钙蛋白值升高的患者较少(肌钙蛋白I为6例,肌钙蛋白T为25例)。
  • 2例发生主要心脏终点事件,31例发生次要心脏终点事件(恢复率为74%,23/31)。

关键数值与推荐

  • 基线肌钙蛋白I升高阈值:>40 ng/L。
  • 基线肌钙蛋白T升高阈值:>14 ng/L。
  • 主要心脏终点:NYHA III或IV级症状性充血性心力衰竭经心脏科医生确认和显著LVEF下降,或明确或可能因心脏原因导致的死亡。
  • 次要心脏终点:确认的显著无症状或轻度症状性LVEF下降。

局限性

  • NT-proBNP因缺乏公认的升高阈值而无法得出类似结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Women receiving trastuzumab with chemotherapy are at risk for trastuzumab-related cardiac dysfunction (TRCD). We explored the prognostic value of cardiac markers (troponins I and T, N-terminal prohormone of brain natriuretic peptide [NT-proBNP]) to predict baseline susceptibility to develop TRCD. We examined whether development of cardiac end points or significant left ventricular ejection fraction (LVEF) drop was associated with markers' increases. Patients and Methods Cardiac marker assessments were coupled with LVEF measurements at different time points for 533 patients from the Herceptin Adjuvant (HERA) study who agreed to participate in this study. Patients with missing marker assessments were excluded, resulting in 452 evaluable patients. A primary cardiac end point was defined as symptomatic congestive heart failure of New York Heart Association class III or IV, confirmed by a cardiologist, and a significant LVEF drop, or death of definite or probable cardiac causes. A secondary cardiac end point was defined as a confirmed significant asymptomatic or mildly symptomatic LVEF drop. Results Elevated baseline troponin I (> 40 ng/L) and T (> 14 ng/L), occurring in 56 of 412 (13.6%) and 101 of 407 (24.8%) patients, respectively, were associated with an increased significant LVEF drop risk (univariate analysis: hazard ratio, 4.52; P < .001 and hazard ratio, 3.57; P < .001, respectively). Few patients had their first elevated troponin value recorded during the study (six patients for troponin I and 25 patients for troponin T). Two patients developed a primary and 31 patients a secondary cardiac end point (recovery rate of 74%, 23 of 31). For NT-proBNP, higher increases from baseline were seen in patients with significant LVEF drop. Conclusion Elevated troponin I or T before trastuzumab is associated with increased risk for TRCD. A similar conclusion for NT-proBNP could not be drawn because of the lack of a well-established elevation threshold; however, higher increases from baseline were seen in patients with TRCD compared with patients without.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Zardavas D, Suter TM, Van Veldhuisen DJ, et al. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy. J Clin Oncol. 2016. PMID: 28199174. doi:10.1200/JCO.2015.65.7916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。